Search This Blog

468x60.

728x90


l TREATMENT CESSATION Associated with a higher risk of

withdrawal reactions. The dose should preferably be

reduced gradually over about 4 weeks, or longer if

withdrawal symptoms emerge (6 months in patients who

have been on long-term maintenance treatment).

l PATIENT AND CARER ADVICE

Driving and skilled tasks Patients should be counselled

about the effect on driving.

l MEDICINAL FORMS There can be variation in the licensing of

different medicines containing the same drug. Forms available

from special-order manufacturers include: oral suspension, oral

solution

Oral suspension

CAUTIONARY AND ADVISORY LABELS 5, 21

▶ Seroxat (GlaxoSmithKline UK Ltd)

Paroxetine (as Paroxetine hydrochloride) 2 mg per 1 ml Seroxat

20mg/10ml liquid sugar-free | 150 ml P £9.12 DT = £9.12

Tablet

CAUTIONARY AND ADVISORY LABELS 21

▶ Paroxetine (Non-proprietary)

Paroxetine (as Paroxetine hydrochloride) 10 mg Paroxetine 10mg

tablets | 28 tablet P £17.03 DT = £5.69

Paroxetine (as Paroxetine hydrochloride) 20 mg Paroxetine 20mg

tablets | 30 tablet P £12.18 DT = £1.12

Paroxetine (as Paroxetine hydrochloride) 30 mg Paroxetine 30mg

tablets | 30 tablet P £2.65 DT = £1.79

Paroxetine (as Paroxetine hydrochloride) 40 mg Paroxetine 40mg

tablets | 28 tablet P £16.99–£17.03 DT = £17.03 | 30 tablet P £18.25–£25.07

▶ Seroxat (GlaxoSmithKline UK Ltd)

Paroxetine (as Paroxetine hydrochloride) 10 mg Seroxat 10mg

tablets | 28 tablet P £14.21 DT = £5.69

Paroxetine (as Paroxetine hydrochloride) 20 mg Seroxat 20mg

tablets | 30 tablet P £15.23 DT = £1.12

Paroxetine (as Paroxetine hydrochloride) 30 mg Seroxat 30mg

tablets | 30 tablet P £26.74 DT = £1.79

eiiiF 363i

Sertraline 19-Mar-2018

l INDICATIONS AND DOSE

Depressive illness

▶ BY MOUTH

▶ Adult: Initially 50 mg daily, then increased in steps of

50 mg at intervals of at least 1 week if required;

maintenance 50 mg daily; maximum 200 mg per day

Obsessive-compulsive disorder

▶ BY MOUTH

▶ Adult: Initially 50 mg daily, then increased in steps of

50 mg at intervals of at least 1 week if required;

maximum 200 mg per day

Panic disorder | Post-traumatic stress disorder | Social

anxiety disorder

▶ BY MOUTH

▶ Adult: Initially 25 mg daily for 1 week, then increased

to 50 mg daily, then increased in steps of 50 mg at

intervals of at least 1 week if required, increase only if

response is partial and if drug is tolerated; maximum

200 mg per day

l INTERACTIONS → Appendix 1: SSRIs

l SIDE-EFFECTS

▶ Common or very common Chest pain . depression . gastrointestinal disorders . increased risk of infection . neuromuscular dysfunction . vasodilation

▶ Uncommon Back pain . burping . chills . cold sweat. dysphagia . dyspnoea . ear pain . euphoric mood . hypertension . hypothyroidism . migraine . muscle

complaints . muscle weakness . oedema . oral disorders . osteoarthritis . periorbital oedema .respiratory disorders . sensation abnormal . speech disorder.thinking abnormal . thirst

▶ Rare or very rare Balanoposthitis . bone disorder. cardiac

disorder. coma . conversion disorder. diabetes mellitus . drug dependence . dysphonia . eye disorders . gait

abnormal . genital discharge . glaucoma . hair texture

abnormal . hepatic disorders . hiccups . hypercholesterolaemia . hypoglycaemia . injury . lymphadenopathy . myocardial infarction . neoplasms . oliguria . peripheral ischaemia . psychotic disorder. vasodilation procedure . vision disorders . vulvovaginal

atrophy

▶ Frequency not known Cerebrovascular insufficiency . gynaecomastia . hyperglycaemia . leucopenia . neuroleptic

malignant syndrome . pancreatitis

l BREAST FEEDING Not known to be harmful but consider

discontinuing breast-feeding.

l HEPATIC IMPAIRMENT Manufacturer advises avoid in

severe impairment (no information available).

Dose adjustments Manufacturer advises dose reduction or

increasing dose interval in mild to moderate impairment.

l RENAL IMPAIRMENT Use with caution.

l TREATMENT CESSATION The dose should preferably be

reduced gradually over about 4 weeks, or longer if

withdrawal symptoms emerge (6 months in patients who

have been on long-term maintenance treatment).

l PATIENT AND CARER ADVICE

Driving and skilled tasks Patients should be counselled on

the effects on driving and skilled tasks.

l MEDICINAL FORMS There can be variation in the licensing of

different medicines containing the same drug. Forms available

from special-order manufacturers include: tablet, oral

suspension

Tablet

▶ Sertraline (Non-proprietary)

Sertraline (as Sertraline hydrochloride) 50 mg Sertraline 50mg

tablets | 28 tablet P £17.00 DT = £0.82

Sertraline (as Sertraline hydrochloride) 100 mg Sertraline 100mg

tablets | 28 tablet P £28.00 DT = £1.08

▶ Lustral (Pfizer Ltd)

Sertraline (as Sertraline hydrochloride) 50 mg Lustral 50mg

tablets | 28 tablet P £17.82 DT = £0.82

Sertraline (as Sertraline hydrochloride) 100 mg Lustral 100mg

tablets | 28 tablet P £29.16 DT = £1.08

ANTIDEPRESSANTS › SEROTONIN AND

NORADRENALINE RE-UPTAKE INHIBITORS

Duloxetine 15-Mar-2017

l DRUG ACTION Inhibits the re-uptake of serotonin and

noradrenaline.

l INDICATIONS AND DOSE

Major depressive disorder

▶ BY MOUTH

▶ Adult: 60 mg once daily continued→

BNF 78 Depression 367

Nervous system

4

Generalised anxiety disorder

▶ BY MOUTH

▶ Adult: Initially 30 mg once daily, increased if necessary

to 60 mg once daily; maximum 120 mg per day

Diabetic neuropathy

▶ BY MOUTH

▶ Adult: 60 mg once daily, discontinue if inadequate

response after 2 months; review treatment at least

every 3 months, maximum dose to be given in divided

doses; maximum 120 mg per day

Moderate to severe stress urinary incontinence

▶ BY MOUTH

▶ Adult (female): 40 mg twice daily, patient should be

assessed for benefit and tolerability after 2–4 weeks,

alternatively initially 20 mg twice daily for 2 weeks, this

can minimise side effects, then increased to 40 mg

twice daily, the patient should be assessed for benefit

and tolerability after 2–4 weeks.

l CAUTIONS Bleeding disorders . cardiac disease . elderly . history of mania . history of seizures . hypertension (avoid

if uncontrolled).raised intra-ocular pressure . susceptibility to angle-closure glaucoma

l INTERACTIONS → Appendix 1: duloxetine

l SIDE-EFFECTS

▶ Common or very common Anxiety . appetite decreased . constipation . diarrhoea . dizziness . drowsiness . dry

mouth . fall . fatigue . flushing . gastrointestinal discomfort . gastrointestinal disorders . headache . muscle complaints . nausea . pain . palpitations . paraesthesia . sexual

dysfunction . skin reactions . sleep disorders . sweat

changes .tinnitus .tremor. urinary disorders . vision

disorders . vomiting . weight changes . yawning

▶ Uncommon Apathy . arrhythmias . behaviour abnormal . burping . chills . concentration impaired . disorientation . dysphagia . ear pain . feeling abnormal . gait abnormal . haemorrhage . hepatic disorders . hyperglycaemia . increased risk of infection . malaise . menstrual disorder. movement disorders . mydriasis . peripheral coldness . photosensitivity reaction . postural hypotension . suicidal

tendencies . syncope .taste altered .temperature sensation

altered .testicular pain .thirst.throat tightness . vertigo

▶ Rare or very rare Angioedema . cutaneous vasculitis . dehydration . galactorrhoea . glaucoma . hallucination . hyperprolactinaemia . hypertensive crisis . hyponatraemia . hypothyroidism . mania . menopausal symptoms . oral

disorders . seizure . serotonin syndrome . SIADH . StevensJohnson syndrome . urine odour abnormal

l PREGNANCY Toxicity in animal studies—avoid in patients

with stress urinary incontinence; in other conditions use

only if potential benefit outweighs risk. Risk of neonatal

withdrawal symptoms if used near term.

l BREAST FEEDING Present in milk—manufacturer advises

avoid.

l HEPATIC IMPAIRMENT Manufacturer advises avoid.

l RENAL IMPAIRMENT Avoid if eGFR less than

30 mL/minute/1.73 m2

.

l TREATMENT CESSATION Nausea, vomiting, headache,

anxiety, dizziness, paraesthesia, sleep disturbances, and

tremor are the most common features of abrupt

withdrawal or marked reduction of the dose; dose should

be reduced over at least 1–2 weeks.

l NATIONAL FUNDING/ACCESS DECISIONS

CYMBALTA ®

Scottish Medicines Consortium (SMC) decisions

▶ With oral use for Diabetic neuropathy The Scottish Medicines

Consortium has advised (September 2006) that duloxetine

(Cymbalta ®) should be restricted for use by specialists

when other treatments for diabetic peripheral neuropathic

pain are unsuitable or inadequate.

l MEDICINAL FORMS There can be variation in the licensing of

different medicines containing the same drug.

Gastro-resistant capsule

CAUTIONARY AND ADVISORY LABELS 2

▶ Duloxetine (Non-proprietary)

Duloxetine (as Duloxetine hydrochloride) 20 mg Duloxetine 20mg

gastro-resistant capsules | 28 capsule P £18.48 DT = £3.53

Duloxetine (as Duloxetine hydrochloride) 30 mg Duloxetine 30mg

gastro-resistant capsules | 28 capsule P £22.40 DT = £1.68

Duloxetine (as Duloxetine hydrochloride) 40 mg Duloxetine 40mg

gastro-resistant capsules | 56 capsule P £36.96 DT = £5.40

Duloxetine (as Duloxetine hydrochloride) 60 mg Duloxetine 60mg

gastro-resistant capsules | 28 capsule P £27.72 DT = £2.37

▶ Cymbalta (Eli Lilly and Company Ltd)

Duloxetine (as Duloxetine hydrochloride) 30 mg Cymbalta 30mg

gastro-resistant capsules | 28 capsule P £22.40 DT = £1.68

Duloxetine (as Duloxetine hydrochloride) 60 mg Cymbalta 60mg

gastro-resistant capsules | 28 capsule P £27.72 DT = £2.37

▶ Depalta (Disposable Medical Equipment Ltd)

Duloxetine (as Duloxetine hydrochloride) 30 mg Depalta 30mg

gastro-resistant capsules | 28 capsule P £2.95 DT = £1.68

Duloxetine (as Duloxetine hydrochloride) 60 mg Depalta 60mg

gastro-resistant capsules | 28 capsule P £4.25 DT = £2.37

▶ Duciltia (Aristo Pharma Ltd)

Duloxetine (as Duloxetine hydrochloride) 30 mg Duciltia 30mg

gastro-resistant capsules | 28 capsule P £22.40 DT = £1.68

Duloxetine (as Duloxetine hydrochloride) 60 mg Duciltia 60mg

gastro-resistant capsules | 28 capsule P £27.72 DT = £2.37

▶ Dutor (Torrent Pharma (UK) Ltd)

Duloxetine (as Duloxetine hydrochloride) 20 mg Dutor 20mg

gastro-resistant capsules | 28 capsule P s DT = £3.53

Duloxetine (as Duloxetine hydrochloride) 30 mg Dutor 30mg

gastro-resistant capsules | 28 capsule P s DT = £1.68

Duloxetine (as Duloxetine hydrochloride) 40 mg Dutor 40mg

gastro-resistant capsules | 56 capsule P s DT = £5.40

Duloxetine (as Duloxetine hydrochloride) 60 mg Dutor 60mg

gastro-resistant capsules | 28 capsule P s DT = £2.37

▶ Yentreve (Eli Lilly and Company Ltd)

Duloxetine (as Duloxetine hydrochloride) 20 mg Yentreve 20mg

gastro-resistant capsules | 28 capsule P £18.48 DT = £3.53

Duloxetine (as Duloxetine hydrochloride) 40 mg Yentreve 40mg

gastro-resistant capsules | 56 capsule P £36.96 DT = £5.40

Venlafaxine 26-Jul-2017

l DRUG ACTION A serotonin and noradrenaline re-uptake

inhibitor.

l INDICATIONS AND DOSE

Major depression

▶ BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

▶ Adult: Initially 75 mg daily in 2 divided doses, then

increased if necessary up to 375 mg daily, dose to be

increased if necessary at intervals of at least 2 weeks,

faster dose titration may be necessary in some

patients; maximum 375 mg per day

▶ BY MOUTH USING MODIFIED-RELEASE MEDICINES

▶ Adult: Initially 75 mg once daily, increased if necessary

up to 375 mg once daily, dose to be increased if

necessary at intervals of at least 2 weeks, faster dose

titration may be necessary in some patients; maximum

375 mg per day

Generalised anxiety disorder

▶ BY MOUTH USING MODIFIED-RELEASE MEDICINES

▶ Adult: 75 mg once daily, increased if necessary up to

225 mg once daily, dose to be increased at intervals of

at least 2 weeks; maximum 225 mg per day

Social anxiety disorder

▶ BY MOUTH USING MODIFIED-RELEASE MEDICINES

▶ Adult: 75 mg once daily, there is no evidence of greater

efficacy at higher doses, increased if necessary up to

225 mg once daily, dose to be increased if necessary at

intervals of at least 2 weeks; maximum 225 mg per day

368 Mental health disorders BNF 78

Nervous system

4

Menopausal symptoms, particularly hot flushes, in women

with breast cancer

▶ BY MOUTH USING MODIFIED-RELEASE MEDICINES

▶ Adult: 37.5 mg once daily for one week, then increased

if necessary to 75 mg once daily

l UNLICENSED USE g Venlafaxine is used for menopausal

symptoms, hbut it is not licensed for this indication.

l CONTRA-INDICATIONS Conditions associated with high risk

of cardiac arrhythmia . uncontrolled hypertension

l CAUTIONS Diabetes . heart disease (monitor blood

pressure). history of bleeding disorders . history of

epilepsy . history or family history of mania . susceptibility

to angle-closure glaucoma

l INTERACTIONS → Appendix 1: venlafaxine

l SIDE-EFFECTS

▶ Common or very common Anxiety . appetite decreased . arrhythmias . asthenia . chills . confusion . constipation . depersonalisation . diarrhoea . dizziness . dry mouth . dyspnoea . headache . hot flush . hypertension . menstrual

cycle irregularities . movement disorders . muscle tone

increased . mydriasis . nausea . palpitations . paraesthesia . sedation . sexual dysfunction . skin reactions . sleep

disorders . sweat changes .taste altered .tinnitus .tremor. urinary disorders . vision disorders . vomiting . weight

changes . yawning

▶ Uncommon Alopecia . angioedema . apathy . behaviour

abnormal . derealisation . haemorrhage . hallucination . hypotension . mood altered . photosensitivity reaction . syncope

▶ Rare or very rare Agranulocytosis . angle closure glaucoma . bone marrow disorders . delirium . hepatitis . hyponatraemia . neuroleptic malignant syndrome . neutropenia . pancreatitis . QT interval prolongation . respiratory disorders .rhabdomyolysis . seizure . serotonin

syndrome . severe cutaneous adverse reactions (SCARs). SIADH .thrombocytopenia

▶ Frequency not known Suicidal tendencies . vertigo . withdrawal syndrome

l PREGNANCY Avoid unless potential benefit outweighs

risk—toxicity in animal studies. Risk of withdrawal effects

in neonate.

l BREAST FEEDING Present in milk—avoid.

l HEPATIC IMPAIRMENT Manufacturer advises caution

(inter-individual variability in clearance; limited

information available in severe impairment).

Dose adjustments Manufacturer advises consider dose

reduction of 50% in mild to moderate impairment and of

more than 50% in severe impairment.

l RENAL IMPAIRMENT Use with caution.

Dose adjustments Use half normal dose (immediate-release

tablets may be given once daily) if eGFR less than

30 mL/minute/1.73 m2

.

l TREATMENT CESSATION Associated with a higher risk of

withdrawal effects compared with other antidepressants.

Gastro-intestinal disturbances, headache, anxiety,

dizziness, paraesthesia, tremor, sleep disturbances, and

sweating are most common features of withdrawal if

treatment stopped abruptly or if dose reduced markedly;

dose should be reduced over several weeks.

l PATIENT AND CARER ADVICE

Driving and skilled tasks May affect performance of skilled

tasks (e.g. driving).

l MEDICINAL FORMS There can be variation in the licensing of

different medicines containing the same drug. Forms available

from special-order manufacturers include: oral suspension, oral

solution

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 3, 21, 25

▶ Sunveniz XL (Sun Pharmaceutical Industries Europe B.V.)

Venlafaxine (as Venlafaxine hydrochloride) 75 mg Sunveniz XL

75mg tablets | 30 tablet P £11.14 DT = £2.60

Venlafaxine (as Venlafaxine hydrochloride) 150 mg Sunveniz XL

150mg tablets | 30 tablet P £18.64 DT = £3.90

▶ Venladex XL (Dexcel-Pharma Ltd)

Venlafaxine (as Venlafaxine hydrochloride) 75 mg Venladex XL

75mg tablets | 28 tablet P £11.20

Venlafaxine (as Venlafaxine hydrochloride) 150 mg Venladex XL

150mg tablets | 28 tablet P £18.70

Venlafaxine (as Venlafaxine hydrochloride) 225 mg Venladex XL

225mg tablets | 28 tablet P £31.36

▶ Venlalic XL (Ethypharm UK Ltd)

Venlafaxine (as Venlafaxine hydrochloride) 37.5 mg Venlalic XL

37.5mg tablets | 30 tablet P £6.60 DT = £6.60

Venlafaxine (as Venlafaxine hydrochloride) 75 mg Venlalic XL

75mg tablets | 30 tablet P £2.60 DT = £2.60

Venlafaxine (as Venlafaxine hydrochloride) 150 mg Venlalic XL

150mg tablets | 30 tablet P £3.90 DT = £3.90

Venlafaxine (as Venlafaxine hydrochloride) 225 mg Venlalic XL

225mg tablets | 30 tablet P £33.60 DT = £33.60

▶ ViePax XL (Dexcel-Pharma Ltd)

Venlafaxine (as Venlafaxine hydrochloride) 75 mg ViePax XL

75mg tablets | 28 tablet P £2.60

Venlafaxine (as Venlafaxine hydrochloride) 150 mg ViePax XL

150mg tablets | 28 tablet P £3.90

Venlafaxine (as Venlafaxine hydrochloride) 225 mg ViePax XL

225mg tablets | 28 tablet P £31.36

Tablet

CAUTIONARY AND ADVISORY LABELS 3

▶ Venlafaxine (Non-proprietary)

Venlafaxine (as Venlafaxine hydrochloride) 37.5 mg Venlafaxine

37.5mg tablets | 56 tablet P £6.99 DT = £2.23

Venlafaxine (as Venlafaxine hydrochloride) 75 mg Venlafaxine

75mg tablets | 56 tablet P £6.06 DT = £3.40

▶ ViePax (Dexcel-Pharma Ltd)

Venlafaxine (as Venlafaxine hydrochloride) 37.5 mg ViePax

37.5mg tablets | 56 tablet P £21.07 DT = £2.23

Venlafaxine (as Venlafaxine hydrochloride) 75 mg ViePax 75mg

tablets | 56 tablet P £35.13 DT = £3.40

Modified-release capsule

CAUTIONARY AND ADVISORY LABELS 3, 21, 25

▶ Venlafaxine (Non-proprietary)

Venlafaxine (as Venlafaxine hydrochloride) 225 mg Venlafaxine

225mg modified-release capsules | 30 capsule P £44.75

▶ Alventa XL (Consilient Health Ltd)

Venlafaxine (as Venlafaxine hydrochloride) 75 mg Alventa XL

75mg capsules | 28 capsule P £19.12 DT = £2.60

Venlafaxine (as Venlafaxine hydrochloride) 150 mg Alventa XL

150mg capsules | 28 capsule P £31.88 DT = £3.90

▶ Apclaven XL (Torrent Pharma (UK) Ltd)

Venlafaxine (as Venlafaxine hydrochloride) 37.5 mg Apclaven XL

37.5mg capsules | 28 capsule P s DT = £5.25

Venlafaxine (as Venlafaxine hydrochloride) 75 mg Apclaven XL

75mg capsules | 28 capsule P s DT = £2.60

Venlafaxine (as Venlafaxine hydrochloride) 150 mg Apclaven XL

150mg capsules | 28 capsule P s DT = £3.90

▶ Depefex XL (Chiesi Ltd)

Venlafaxine (as Venlafaxine hydrochloride) 75 mg Depefex XL

75mg capsules | 28 capsule P £10.40 DT = £2.60

Venlafaxine (as Venlafaxine hydrochloride) 150 mg Depefex XL

150mg capsules | 28 capsule P £17.40 DT = £3.90

▶ Efexor XL (Pfizer Ltd)

Venlafaxine (as Venlafaxine hydrochloride) 75 mg Efexor XL 75mg

capsules | 28 capsule P £22.08 DT = £2.60

Venlafaxine (as Venlafaxine hydrochloride) 150 mg Efexor XL

150mg capsules | 28 capsule P £36.81 DT = £3.90

Venlafaxine (as Venlafaxine hydrochloride) 225 mg Efexor XL

225mg capsules | 28 capsule P £47.11 DT = £47.11

▶ Majoven XL (Bristol Laboratories Ltd)

Venlafaxine (as Venlafaxine hydrochloride) 37.5 mg Majoven XL

37.5mg capsules | 28 capsule P £5.25 DT = £5.25

BNF 78 Depression 369

Nervous system

4

No comments:

Post a Comment

اكتب تعليق حول الموضوع

mcq general

 

Search This Blog